Document is current
Any future updates will be listed below
-
Authors
Tsiara, Ioanna
Correia, Mario S. P.
Yang, Fan
Zeng, Weiming
Seeburger, Pauline
Hervás Povo, Belén
Lundgaard, Iben
Menéndez-González, Manuel
Vujasinovic, Miroslav
Löhr, J.-Matthias
Globisch, Daniel https://orcid.org/0000-0002-4526-5788
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2020-04707)
Cancerfonden (22 2449 Pj)
H2020 European Research Council (101096309)
Uppsala University
- License Information
-
More Information
Article History
Received: 14 July 2025
Revised: 4 August 2025
Accepted: 5 August 2025
First Online: 1 September 2025
Declarations
:
: Sample group I—CSF samples: All human CSF samples were obtained in accordance with the World Medical Association Declaration of Helsinki, and all patients gave written informed consent. Approval for the study was obtained from the ethical committee at Hospital Universitario Central de Asturias (HUCA) (No 275/19). All samples were collected at Hospital Universitario Central de Asturias and stored at − 80 °C. All patient codes have been removed in this publication.Sample group II—Fecal and plasma samples: Fecal and plasma samples were obtained from high-risk pancreatic cancer patients in accordance with the World Medical Association Declaration of Helsinki, and all patients gave written informed consent. Approval for the study was obtained from the ethical committee at Karolinska University Hospital (ethical approval number: Dnr2017/290–31). Plasma and fecal samples were collected using routine clinical collection protocols at Karolinska University Hospital, and all patient codes have been removed in this publication. All samples were stored at − 80 °C.
: The authors declare no competing interests.
